Abstract

The overall theme of the Duke RBL will be provision of facilities for the study of host defense and microbial pathogenesis of select agents and emerging infections with emphasis on work performed in the Region IV Regional Center of Excellence For Biodefense and Emerging Infections (RCE). The Duke RBL will provide a state-of-the-art BSL-2/BSL-3 biocontainment facility that will have research cores and laboratories to study the cell and molecular biology of select agents and emerging infections, and provide a central location that will focus the activities of investigators throughout Duke University and the region on select agent basic and translational research. Duke's prior 30-year history of having an NIH-built biocontainment facility on site (the Cancer Center Isolation Facility), coupled with Duke University as the headquarters and lead institution for the Region IV Southeast Regional Center of Excellence in Biodefense and Emerging Infections (SERCEB), are important strengths of this RBL application. Construction of the Duke RBL will ensure that a major component of the Region IV RCE will be able to meet the goals of developing vaccines, drugs and vaccines for select agents.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Construction Cooperative Agreement (UC6)
Project #
1UC6AI058607-01
Application #
6712172
Study Section
Special Emphasis Panel (ZAI1-RCG-M (S1))
Program Officer
Lewis, Ambrose B
Project Start
2003-09-30
Project End
2008-06-30
Budget Start
2003-09-30
Budget End
2008-06-30
Support Year
1
Fiscal Year
2003
Total Cost
$11,970,523
Indirect Cost

  Institution

Name
Duke University
Department
Type
Schools of Medicine
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705

  Publications

Junkins, Robert D; Gallovic, Matthew D; Johnson, Brandon M et al. (2018) A robust microparticle platform for a STING-targeted adjuvant that enhances both humoral and cellular immunity during vaccination. J Control Release 270:1-13
Zhang, Xin; Hartung, Jane E; Bortsov, Andrey V et al. (2018) Sustained stimulation of ?2- and ?3-adrenergic receptors leads to persistent functional pain and neuroinflammation. Brain Behav Immun 73:520-532
Zhu, Weiyan; Tomberg, Joshua; Knilans, Kayla J et al. (2018) Properly folded and functional PorB from Neisseria gonorrhoeae inhibits dendritic cell stimulation of CD4+ T cell proliferation. J Biol Chem 293:11218-11229
Zheng, Xiaojing; O'Connell, Catherine M; Zhong, Wujuan et al. (2018) Discovery of Blood Transcriptional Endotypes in Women with Pelvic Inflammatory Disease. J Immunol 200:2941-2956
McCarthy, Kevin R; Watanabe, Akiko; Kuraoka, Masayuki et al. (2018) Memory B Cells that Cross-React with Group 1 and Group 2 Influenza A Viruses Are Abundant in Adult Human Repertoires. Immunity 48:174-184.e9
Collier, Michael A; Junkins, Robert D; Gallovic, Matthew D et al. (2018) Acetalated Dextran Microparticles for Codelivery of STING and TLR7/8 Agonists. Mol Pharm 15:4933-4946
Hayashi, Tomonori; Lynch, Heather E; Geyer, Susan et al. (2018) Impact of early life exposure to ionizing radiation on influenza vaccine response in an elderly Japanese cohort. Vaccine 36:6650-6659
Walter, Emmanuel B; Hornik, Christoph P; Grohskopf, Lisa et al. (2017) The effect of antipyretics on immune response and fever following receipt of inactivated influenza vaccine in young children. Vaccine 35:6664-6671
Jin, Cong; Shelburne, Christopher P; Li, Guojie et al. (2017) Particulate allergens potentiate allergic asthma in mice through sustained IgE-mediated mast cell activation. J Clin Invest 127:3913
McKay, Heather S; Margolick, Joseph B; Martínez-Maza, Otoniel et al. (2017) Multiplex assay reliability and long-term intra-individual variation of serologic inflammatory biomarkers. Cytokine 90:185-192

Showing the most recent 10 out of 100 publications